Sientra (SIEN) Rating Increased to Hold at Zacks Investment Research
Sientra (NASDAQ:SIEN) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
A number of other analysts also recently weighed in on the stock. BidaskClub downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. Dougherty & Co assumed coverage on shares of Sientra in a research report on Thursday, August 30th. They issued a “buy” rating and a $31.00 price target on the stock. Stephens reiterated a “buy” rating and issued a $30.00 price target on shares of Sientra in a research report on Thursday, August 9th. Stifel Nicolaus increased their price target on shares of Sientra from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Canaccord Genuity increased their price target on shares of Sientra from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $22.50.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $16.90 million during the quarter, compared to analyst estimates of $16.66 million. Sientra had a negative net margin of 126.03% and a negative return on equity of 132.84%. The business’s revenue was up 72.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.74) earnings per share. On average, equities analysts anticipate that Sientra will post -3.02 earnings per share for the current year.
In other Sientra news, CEO Jeffrey M. Nugent sold 1,852 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $24.90, for a total transaction of $46,114.80. Following the sale, the chief executive officer now directly owns 297,999 shares in the company, valued at approximately $7,420,175.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy Haines sold 89,651 shares of the firm’s stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the sale, the director now owns 37,662 shares in the company, valued at $811,992.72. The disclosure for this sale can be found here. Company insiders own 31.00% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in Sientra by 93.4% during the 2nd quarter. Millennium Management LLC now owns 858,206 shares of the medical instruments supplier’s stock worth $16,744,000 after buying an additional 414,418 shares during the period. Accredited Investors Inc. acquired a new stake in Sientra during the 3rd quarter worth approximately $200,000. Castleark Management LLC acquired a new stake in Sientra during the 2nd quarter worth approximately $2,958,000. Sei Investments Co. raised its holdings in Sientra by 1,701.3% during the 2nd quarter. Sei Investments Co. now owns 55,103 shares of the medical instruments supplier’s stock worth $1,076,000 after buying an additional 52,044 shares during the period. Finally, Cortina Asset Management LLC acquired a new stake in Sientra during the 2nd quarter worth approximately $6,516,000. Hedge funds and other institutional investors own 88.39% of the company’s stock.
Sientra Company Profile
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Featured Story: What are no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.